Form 4: Recursion Pharmaceuticals Director Dean Y. Li Reports Stock Acquisition
SEC Form 4 Filing
Director Dean Y. Li reports acquiring shares of Recursion Pharmaceuticals through the company's Outside Director Compensation Policy.
Summary
- On April 1, 2024, Dean Y. Li, a director at Recursion Pharmaceuticals, acquired 1,267 shares of Class A Common Stock at $0 per share.
- Following the transaction, Li directly owns 59,089 shares of Class A Common Stock.
- Li also indirectly owns 1,422,048 shares through the Dean Y. Li Revocable Trust, 1,269,796 shares through the Dean Y. Li GRAT, and 421,000 shares through the Dean Y. Li 2021 Family Trust.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock acquisition under a compensation plan. The director's increased stake could be seen as mildly positive.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Shares transferred by the reporting person to the GRAT |
| 04/01/2024 | Date of transaction: Acquisition of Class A Common Stock |
| 04/03/2024 | Date of signature by attorney-in-fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.